Embolotherapy Global Market - Forecast to 2029
Embolotherapy involves the percutaneous endovascular use of one or more of a variety of agents and has evolved as a minimally invasive procedure for controlling blood loss during complicated surgical procedures involving laparoscopic, neurovascular, uterine fibroids, arteriovenous malformations, hepatocellular carcinomas, benign prostate hyperplasia (BPH), neurovascular, intracranial and peripheral vasculatures related surgeries.
According to IQ4I analysis, the Embolotherapy global market is expected to grow at mid single digit CAGR from 2022 to 2029 to reach $6,115.9 million by 2029. The Embolotherapy market is segmented based on products, applications, procedures, end-users and geography. The Embolotherapy products market is segmented into temporary agents, permanent agents, Radioembolization, and supporting devices, among them, permanent agents held the largest share of the market in 2022 and are expected to grow at high single digit CAGR from 2022 to 2029. The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029. Temporary agents are further sub-segmented into autologous agents and Resorbable gelatin sponges, of this, the Resorbable gelatin sponge accounted for the largest share in 2022 and are expected to grow at mid single digit CAGR from 2022 to 2029. The permanent agents market is further sub-segmented into particle agents, coils, liquid embolization agents, flow diverters and others, among which the coils segment commanded the largest share in 2022 and is expected to grow at low single digit CAGR from 2022 to 2029. The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029. The particle agents are further segmented into poly vinyl alcohol (PVA) and microspheres, among which the microspheres segment commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The coils are further segmented into pushable and detachable coils among which the detachable coils commanded the largest share in 2022, the segment is expected to grow at low single digit CAGR from 2022 to 2029.
The applications market is segmented into neurology, oncology, peripheral vascular diseases, urology and others, among them, the neurology segment held the largest share of 44.5% in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The urology segment is expected to grow at high single digit CAGR from 2022 to 2029. The neurology application market is sub-segmented into the intracranial aneurysm and arteriovenous malformation (AVM), of this, the intracranial aneurysm segment command the largest revenue in 2022, the AVM segment is expected to grow at high single digit CAGR from 2022 to 2029. The oncology market is further sub-segmented into liver cancer, lung cancer, and others, of this, the lung cancer segment commanded the largest revenue in 2022 and the market is expected to grow at high single digit CAGR from 2022 to 2029.
Based on Procedures the embolotherapy global market is segmented into Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Chemoembolization (TACE), and Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), among them, TAE commanded the largest share in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029, the TARE/SIRT segmented is expected to grow at high single digit CAGR from 2022 to 2029. The Transcatheter Arterial Chemoembolization (TACE) market is segmented into drug-eluting beads-TACE and conventional TACE, among which the cTACE commanded the largest revenue in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029.
The end-users market is classified into hospitals, ambulatory surgical centers and others. Among them, the hospital commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The ambulatory surgical center is expected to grow at high single digit CAGR from 2022 to 2029.
Geographically, North America is the largest market, followed by Europe and the Asia Pacific. The APAC region is the fastest-growing region and is expected to grow at high single digit CAGR from 2022 to 2029 presenting an array of growth opportunities and is likely to get the attention of new investors in the Embolotherapy market. Growth in the Asian market is attributed to the rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.
Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.
On the other hand, side effects, complications, and risks associated with embolization and lack of skilled and trained professionals are restraining the market growth, while increasing product recalls, competition from alternative therapies and stringent regulatory requirements for product development and approvals are threatening the market growth.
The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Major players in the embolotherapy market include Medtronic, PLC (Ireland), Microport Scientific (China), Boston Scientific Corporation (U.S.), Stryker (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Sirtex (CDH) (China), Johnson & Johnson (U.S.), Balt Group (France), Kaneka Corporation (Japan), Merit Medical (U.S.), Cook Medical (U.S.), Siemens Healthineers (Varian) (Germany), and Guerbet (France).
According to IQ4I analysis, the Embolotherapy global market is expected to grow at mid single digit CAGR from 2022 to 2029 to reach $6,115.9 million by 2029. The Embolotherapy market is segmented based on products, applications, procedures, end-users and geography. The Embolotherapy products market is segmented into temporary agents, permanent agents, Radioembolization, and supporting devices, among them, permanent agents held the largest share of the market in 2022 and are expected to grow at high single digit CAGR from 2022 to 2029. The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029. Temporary agents are further sub-segmented into autologous agents and Resorbable gelatin sponges, of this, the Resorbable gelatin sponge accounted for the largest share in 2022 and are expected to grow at mid single digit CAGR from 2022 to 2029. The permanent agents market is further sub-segmented into particle agents, coils, liquid embolization agents, flow diverters and others, among which the coils segment commanded the largest share in 2022 and is expected to grow at low single digit CAGR from 2022 to 2029. The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029. The particle agents are further segmented into poly vinyl alcohol (PVA) and microspheres, among which the microspheres segment commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The coils are further segmented into pushable and detachable coils among which the detachable coils commanded the largest share in 2022, the segment is expected to grow at low single digit CAGR from 2022 to 2029.
The applications market is segmented into neurology, oncology, peripheral vascular diseases, urology and others, among them, the neurology segment held the largest share of 44.5% in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The urology segment is expected to grow at high single digit CAGR from 2022 to 2029. The neurology application market is sub-segmented into the intracranial aneurysm and arteriovenous malformation (AVM), of this, the intracranial aneurysm segment command the largest revenue in 2022, the AVM segment is expected to grow at high single digit CAGR from 2022 to 2029. The oncology market is further sub-segmented into liver cancer, lung cancer, and others, of this, the lung cancer segment commanded the largest revenue in 2022 and the market is expected to grow at high single digit CAGR from 2022 to 2029.
Based on Procedures the embolotherapy global market is segmented into Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Chemoembolization (TACE), and Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), among them, TAE commanded the largest share in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029, the TARE/SIRT segmented is expected to grow at high single digit CAGR from 2022 to 2029. The Transcatheter Arterial Chemoembolization (TACE) market is segmented into drug-eluting beads-TACE and conventional TACE, among which the cTACE commanded the largest revenue in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029.
The end-users market is classified into hospitals, ambulatory surgical centers and others. Among them, the hospital commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The ambulatory surgical center is expected to grow at high single digit CAGR from 2022 to 2029.
Geographically, North America is the largest market, followed by Europe and the Asia Pacific. The APAC region is the fastest-growing region and is expected to grow at high single digit CAGR from 2022 to 2029 presenting an array of growth opportunities and is likely to get the attention of new investors in the Embolotherapy market. Growth in the Asian market is attributed to the rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.
Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.
On the other hand, side effects, complications, and risks associated with embolization and lack of skilled and trained professionals are restraining the market growth, while increasing product recalls, competition from alternative therapies and stringent regulatory requirements for product development and approvals are threatening the market growth.
The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Major players in the embolotherapy market include Medtronic, PLC (Ireland), Microport Scientific (China), Boston Scientific Corporation (U.S.), Stryker (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Sirtex (CDH) (China), Johnson & Johnson (U.S.), Balt Group (France), Kaneka Corporation (Japan), Merit Medical (U.S.), Cook Medical (U.S.), Siemens Healthineers (Varian) (Germany), and Guerbet (France).
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Growing patient population with chronic conditions increasing the demand for embolization procedures
3.3.1.2 Technological advancements
3.3.1.3 Acquisitions and collaborations as a growth strategy
3.3.1.4 Increase in product approvals
3.3.1.5 Growth opportunities in emerging markets
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects, complications, and risks associated with embolization
3.3.2.2 Lack of skilled and trained professionals
3.3.2.3 Increasing product recalls
3.3.2.4 Competition from alternative therapies
3.3.2.5 Stringent regulatory requirements for product development and approvals
3.4 REGULATORY AFFAIRS
3.4.1 THE U.S.
3.4.2 CHINA
3.4.3 EUROPE
3.4.4 JAPAN
3.4.5 INDIA
3.5 FUNDING
3.6 DEALS
3.7 PRODUCT APPROVALS AND LAUNCHES
3.8 TECHNOLOGY ADVANCEMENTS
3.8.1 GPX EMBOLIC DEVICE
3.8.2 HYDRAULICALLY ACTUATED SOFT ROBOTIC STEERABLE MICRO-CATHETER
3.8.3 SHAPE MEMORY POLYMER (SMP) TECHNOLOGY
3.8.4 BIODEGRADABLE EMBOLIZATION AGENTS
3.8.5 EMBOLIZATION IN PAIN MANAGEMENT OF OSTEOARTHRITIS
3.8.6 INSTYLLA-HYDROGEL EMBOLIC SYSTEM (HES)
3.8.7 MICROFLUIDICS IN MANUFACTURING OF MICROSPHERES
3.8.8 MICROBOTS IN SWARMS FOR EMBOLIZATION
3.8.9 BISMUTH (BI)-BASED LIQUID EMBOLIC AGENT
3.8.10 FAIR-EMBO PROJECT
3.8.11 BIOCURE-LIQIGEL AGENT
3.8.12 WATER SOLUBLE POLYMERS AS EMBOLIC AGENT
3.8.13 NANOPARTICLES IN TUMOR EMBOLIZATION THERAPY
3.8.14 GAS EMBOLIZATION (GE) USING ACOUSTIC DROPLET VAPORIZATION(ADV) TECHNOLOGY
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 COMPETITIVE RIVALRY
3.9.4 BARGAINING POWER OF SUPPLIERS
3.9.5 BARGAINING POWER OF BUYERS
3.10 CLINICAL TRIALS
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.11.1 EMBOLOTHERAPY MARKET SHARE ANALYSIS
3.11.2 COILS MARKET SHARE ANALYSIS
3.11.3 FLOW DIVERTERS & DISRUPTORS MARKET SHARE ANALYSIS
3.11.4 RADIOEMBOLIZATION MARKET SHARE ANALYSIS
3.12 VOLUME OF NEUROVASCULAR COIL-ASSISTED PROCEDURES
3.12.1 NEUROVASCULAR COILS GLOBAL MARKET
3.13 PRODUCT MATRIX OF SELECTED COMPANIES
4 EMBOLOTHERAPY GLOBAL MARKET, BASED ON PRODUCTS
4.1 INTRODUCTION
4.2 TEMPORARY AGENTS
4.2.1 AUTOLOGOUS AGENTS
4.2.2 RESORBABLE GELATIN SPONGE
4.3 PERMANENT AGENTS
4.3.1 PARTICLE AGENTS
4.3.1.1 Poly vinyl alcohol (PVA)
4.3.1.2 Microspheres
4.3.2 COILS
4.3.2.1 Pushable Coils
4.3.2.2 Detachable Coils
4.3.3 LIQUID EMBOLIZATION AGENTS (LEAS)
4.3.4 FLOW DIVERTERS & FLOW DISRUPTORS
4.3.5 OTHERS
4.4 RADIOEMBOLIZATION
4.5 SUPPORTING DEVICES
5 EMBOLOTHERAPY GLOBAL MARKET, BASED ON THE APPLICATION
5.1 INTRODUCTION
5.2 NEUROLOGY
5.2.1 INTRACRANIAL ANEURYSM
5.2.2 ARTERIOVENOUS MALFORMATIONS (AVM)
5.3 ONCOLOGY
5.3.1 LIVER CANCER
5.3.2 LUNG CANCER
5.3.3 OTHER CANCER
5.4 PERIPHERAL VASCULAR DISEASES (PVD)
5.5 UROLOGY
5.6 OTHER APPLICATIONS
6 EMBOLOTHERAPY GLOBAL MARKET, BASED ON PROCEDURE
6.1 INTRODUCTION
6.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE)
6.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
6.3.1 DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE)
6.3.2 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (cTACE)
6.4 TRANS-ARTERIAL EMBOLIZATION(TARE)/ SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
7 EMBOLOTHERAPY GLOBAL MARKET, BASED ON END-USER
7.1 INTRODUCTION
7.2 HOSPITALS
7.3 AMBULATORY SURGICAL CENTERS
7.4 OTHER END-USERS
8 EMBOLOTHERAPY GLOBAL MARKET, BASED ON REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 U.S.
8.2.2 REST OF NORTH AMERICA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 FRANCE
8.3.3 ITALY
8.3.4 REST OF EUROPE
8.4 APAC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 REST OF APAC
8.5 REST OF THE WORLD
8.5.1 BRAZIL
8.5.2 REST OF SOUTH AMERICA
8.5.3 MIDDLE EAST AND AFRICA
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 APPROVAL
9.3 ACQUISITION
9.4 AGREEMENTS
9.5 NEW PRODUCT LAUNCH
9.6 OTHERS
10 MAJOR COMPANIES
10.1 BALT GROUP
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCT PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS
10.2 BOSTON SCIENTIFIC CORPORATION
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCT PORTFOLIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS
10.3 JOHNSON & JOHNSON
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCT PORTFOLIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS
10.4 KANEKA CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCT PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY
10.4.6 SWOT ANALYSIS
10.5 MEDTRONIC, PLC
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCT PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS
10.6 MERIT MEDICAL SYSTEMS, INC
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCT PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS
10.7 PENUMBRA, INC
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STRATEGY
10.7.6 SWOT ANALYSIS
10.8 SIRTEX MEDICAL INC.
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY DEVELOPMENTS
10.8.5 BUSINESS STRATEGY
10.8.6 SWOT ANALYSIS
10.9 STRYKER CORPORATION
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS
10.10 TERUMO CORPORATION
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCT PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Growing patient population with chronic conditions increasing the demand for embolization procedures
3.3.1.2 Technological advancements
3.3.1.3 Acquisitions and collaborations as a growth strategy
3.3.1.4 Increase in product approvals
3.3.1.5 Growth opportunities in emerging markets
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects, complications, and risks associated with embolization
3.3.2.2 Lack of skilled and trained professionals
3.3.2.3 Increasing product recalls
3.3.2.4 Competition from alternative therapies
3.3.2.5 Stringent regulatory requirements for product development and approvals
3.4 REGULATORY AFFAIRS
3.4.1 THE U.S.
3.4.2 CHINA
3.4.3 EUROPE
3.4.4 JAPAN
3.4.5 INDIA
3.5 FUNDING
3.6 DEALS
3.7 PRODUCT APPROVALS AND LAUNCHES
3.8 TECHNOLOGY ADVANCEMENTS
3.8.1 GPX EMBOLIC DEVICE
3.8.2 HYDRAULICALLY ACTUATED SOFT ROBOTIC STEERABLE MICRO-CATHETER
3.8.3 SHAPE MEMORY POLYMER (SMP) TECHNOLOGY
3.8.4 BIODEGRADABLE EMBOLIZATION AGENTS
3.8.5 EMBOLIZATION IN PAIN MANAGEMENT OF OSTEOARTHRITIS
3.8.6 INSTYLLA-HYDROGEL EMBOLIC SYSTEM (HES)
3.8.7 MICROFLUIDICS IN MANUFACTURING OF MICROSPHERES
3.8.8 MICROBOTS IN SWARMS FOR EMBOLIZATION
3.8.9 BISMUTH (BI)-BASED LIQUID EMBOLIC AGENT
3.8.10 FAIR-EMBO PROJECT
3.8.11 BIOCURE-LIQIGEL AGENT
3.8.12 WATER SOLUBLE POLYMERS AS EMBOLIC AGENT
3.8.13 NANOPARTICLES IN TUMOR EMBOLIZATION THERAPY
3.8.14 GAS EMBOLIZATION (GE) USING ACOUSTIC DROPLET VAPORIZATION(ADV) TECHNOLOGY
3.9 PORTER’S FIVE FORCE ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 COMPETITIVE RIVALRY
3.9.4 BARGAINING POWER OF SUPPLIERS
3.9.5 BARGAINING POWER OF BUYERS
3.10 CLINICAL TRIALS
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.11.1 EMBOLOTHERAPY MARKET SHARE ANALYSIS
3.11.2 COILS MARKET SHARE ANALYSIS
3.11.3 FLOW DIVERTERS & DISRUPTORS MARKET SHARE ANALYSIS
3.11.4 RADIOEMBOLIZATION MARKET SHARE ANALYSIS
3.12 VOLUME OF NEUROVASCULAR COIL-ASSISTED PROCEDURES
3.12.1 NEUROVASCULAR COILS GLOBAL MARKET
3.13 PRODUCT MATRIX OF SELECTED COMPANIES
4 EMBOLOTHERAPY GLOBAL MARKET, BASED ON PRODUCTS
4.1 INTRODUCTION
4.2 TEMPORARY AGENTS
4.2.1 AUTOLOGOUS AGENTS
4.2.2 RESORBABLE GELATIN SPONGE
4.3 PERMANENT AGENTS
4.3.1 PARTICLE AGENTS
4.3.1.1 Poly vinyl alcohol (PVA)
4.3.1.2 Microspheres
4.3.2 COILS
4.3.2.1 Pushable Coils
4.3.2.2 Detachable Coils
4.3.3 LIQUID EMBOLIZATION AGENTS (LEAS)
4.3.4 FLOW DIVERTERS & FLOW DISRUPTORS
4.3.5 OTHERS
4.4 RADIOEMBOLIZATION
4.5 SUPPORTING DEVICES
5 EMBOLOTHERAPY GLOBAL MARKET, BASED ON THE APPLICATION
5.1 INTRODUCTION
5.2 NEUROLOGY
5.2.1 INTRACRANIAL ANEURYSM
5.2.2 ARTERIOVENOUS MALFORMATIONS (AVM)
5.3 ONCOLOGY
5.3.1 LIVER CANCER
5.3.2 LUNG CANCER
5.3.3 OTHER CANCER
5.4 PERIPHERAL VASCULAR DISEASES (PVD)
5.5 UROLOGY
5.6 OTHER APPLICATIONS
6 EMBOLOTHERAPY GLOBAL MARKET, BASED ON PROCEDURE
6.1 INTRODUCTION
6.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE)
6.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
6.3.1 DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE)
6.3.2 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (cTACE)
6.4 TRANS-ARTERIAL EMBOLIZATION(TARE)/ SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
7 EMBOLOTHERAPY GLOBAL MARKET, BASED ON END-USER
7.1 INTRODUCTION
7.2 HOSPITALS
7.3 AMBULATORY SURGICAL CENTERS
7.4 OTHER END-USERS
8 EMBOLOTHERAPY GLOBAL MARKET, BASED ON REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 U.S.
8.2.2 REST OF NORTH AMERICA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 FRANCE
8.3.3 ITALY
8.3.4 REST OF EUROPE
8.4 APAC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 REST OF APAC
8.5 REST OF THE WORLD
8.5.1 BRAZIL
8.5.2 REST OF SOUTH AMERICA
8.5.3 MIDDLE EAST AND AFRICA
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 APPROVAL
9.3 ACQUISITION
9.4 AGREEMENTS
9.5 NEW PRODUCT LAUNCH
9.6 OTHERS
10 MAJOR COMPANIES
10.1 BALT GROUP
10.1.1 OVERVIEW
10.1.2 FINANCIALS
10.1.3 PRODUCT PORTFOLIO
10.1.4 KEY DEVELOPMENTS
10.1.5 BUSINESS STRATEGY
10.1.6 SWOT ANALYSIS
10.2 BOSTON SCIENTIFIC CORPORATION
10.2.1 OVERVIEW
10.2.2 FINANCIALS
10.2.3 PRODUCT PORTFOLIO
10.2.4 KEY DEVELOPMENTS
10.2.5 BUSINESS STRATEGY
10.2.6 SWOT ANALYSIS
10.3 JOHNSON & JOHNSON
10.3.1 OVERVIEW
10.3.2 FINANCIALS
10.3.3 PRODUCT PORTFOLIO
10.3.4 KEY DEVELOPMENTS
10.3.5 BUSINESS STRATEGY
10.3.6 SWOT ANALYSIS
10.4 KANEKA CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIALS
10.4.3 PRODUCT PORTFOLIO
10.4.4 KEY DEVELOPMENTS
10.4.5 BUSINESS STRATEGY
10.4.6 SWOT ANALYSIS
10.5 MEDTRONIC, PLC
10.5.1 OVERVIEW
10.5.2 FINANCIALS
10.5.3 PRODUCT PORTFOLIO
10.5.4 KEY DEVELOPMENTS
10.5.5 BUSINESS STRATEGY
10.5.6 SWOT ANALYSIS
10.6 MERIT MEDICAL SYSTEMS, INC
10.6.1 OVERVIEW
10.6.2 FINANCIALS
10.6.3 PRODUCT PORTFOLIO
10.6.4 KEY DEVELOPMENTS
10.6.5 BUSINESS STRATEGY
10.6.6 SWOT ANALYSIS
10.7 PENUMBRA, INC
10.7.1 OVERVIEW
10.7.2 FINANCIALS
10.7.3 PRODUCT PORTFOLIO
10.7.4 KEY DEVELOPMENTS
10.7.5 BUSINESS STRATEGY
10.7.6 SWOT ANALYSIS
10.8 SIRTEX MEDICAL INC.
10.8.1 OVERVIEW
10.8.2 FINANCIALS
10.8.3 PRODUCT PORTFOLIO
10.8.4 KEY DEVELOPMENTS
10.8.5 BUSINESS STRATEGY
10.8.6 SWOT ANALYSIS
10.9 STRYKER CORPORATION
10.9.1 OVERVIEW
10.9.2 FINANCIALS
10.9.3 PRODUCT PORTFOLIO
10.9.4 KEY DEVELOPMENTS
10.9.5 BUSINESS STRATEGY
10.9.6 SWOT ANALYSIS
10.10 TERUMO CORPORATION
10.10.1 OVERVIEW
10.10.2 FINANCIALS
10.10.3 PRODUCT PORTFOLIO
10.10.4 KEY DEVELOPMENTS
10.10.5 BUSINESS STRATEGY
10.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 2 NEUROVASCULAR COILS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 3 NUMBER OF NEUROVASCULAR COILS UNITS SOLD GLOBALLY, BASED ON REGION (2021-2029) (NOS)
TABLE 4 INTRACRANIAL ANEURYSM GLOBAL PROCEDURAL VOLUME, BASED ON REGION, (2021-2029) ($MN)
TABLE 5 NEUROVASCULAR COIL UNITS SOLD AND INTRACRANIAL ANEURYSM PROCEDURES, BASED ON COUNTRIES (2022) (NOS)
TABLE 6 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 7 TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 8 TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 9 AUTOLOGOUS AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 10 RESORBABLE GELATIN SPONGE GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 11 PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
TABLE 12 PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 13 PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 14 PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 15 POLYVINYL ALCOHOL (PVA) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 16 MICROSPHERES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 17 COILS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 18 COILS GLOBAL MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 19 PUSHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 20 DETACHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 21 LIQUID EMBOLIZATION AGENTS GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) ($MN)
TABLE 22 FLOW DIVERTERS & FLOW DISRUPTORS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 23 OTHER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 24 RADIOEMBOLIZATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 25 SUPPORTING DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 26 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 27 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 28 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 29 INTRACRANIAL ANEURYSM GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) ($MN)
TABLE 30 ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 31 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 32 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 33 LIVER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 34 LUNG CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 35 OTHER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 36 PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 37 UROLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 38 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 39 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PROCEDURE (2021-2029) ($MN)
TABLE 40 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 41 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 42 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 43 DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE)GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 44 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (CTACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 45 SELECTIVE INTERNAL RADIATION THERAPY (SIRT) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 46 TAE AND DEB-TACE PRODUCTS MATRIX
TABLE 47 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 48 HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 49 AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 50 OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 51 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 52 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 53 NORTH AMERICAN TEMPORARY AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 54 NORTH AMERICAN PERMANENT AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 55 NORTH AMERICAN PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 56 NORTH AMERICAN COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 57 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 58 NORTH AMERICAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 59 NORTH AMERICAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 60 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 61 NORTH AMERICAN TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 62 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON END-USER (2021-2029) ($MN)
TABLE 63 NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON COUNTRY (2021-2029) ($MN)
TABLE 64 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 65 EUROPEAN TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 66 EUROPEAN PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 67 EUROPEAN PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 68 EUROPEAN COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 69 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 70 EUROPEAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 71 EUROPEAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 72 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 73 EUROPEAN TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 74 EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 75 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 76 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 77 ASIA-PACIFIC TEMPORARY AGENTS MARKET REVENUE,
BASED ON PRODUCT (2021-2029) ($MN)
TABLE 78 ASIA-PACIFIC PERMANENT AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 79 ASIA-PACIFIC PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 80 ASIA-PACIFIC COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 81 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 82 ASIA-PACIFIC NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 83 ASIA-PACIFIC ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 84 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 85 ASIA-PACIFIC TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 86 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 87 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 88 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 89 ROW TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 90 ROW PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 91 ROW PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 92 ROW COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 93 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 94 ROW NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 95 ROW ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 96 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 97 ROW TACE MARKET REVENUE, BASED ON THERAPY AGENTS (2021-2029) ($MN)
TABLE 98 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 99 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 100 APPROVALS (2020-2022)
TABLE 101 ACQUISITION (2020-2022)
TABLE 102 AGREEMENTS (2020-2022)
TABLE 103 NEW PRODUCT LAUNCH (2020-2022)
TABLE 104 OTHERS (2020-2022)
TABLE 105 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
TABLE 106 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q3) ($MN)
TABLE 107 BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR SUB-SEGMENT TOTAL REVENUE, (2022)(Q3) ($MN)
TABLE 108 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 109 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
TABLE 110 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 111 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 112 KANEKA CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 113 KANEKA CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 114 KANEKA CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 115 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 116 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 117 MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 118 MEDTRONIC, PLC: NEUROSCIENCES TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 119 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 120 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
TABLE 121 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 122 MERIT MEDICAL SYSTEMS, INC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN)
TABLE 123 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) ($MN)
TABLE 124 PENUMBRA, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 125 PENUMBRA, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 126 PENUMBRA, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3)($MN)
TABLE 127 STRYKER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 128 STRYKER CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 129 STRYKER CORPORATION: TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN)
TABLE 130 STRYKER CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 131 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 132 TERUMO CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 133 TERUMO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 1 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 2 NEUROVASCULAR COILS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 3 NUMBER OF NEUROVASCULAR COILS UNITS SOLD GLOBALLY, BASED ON REGION (2021-2029) (NOS)
TABLE 4 INTRACRANIAL ANEURYSM GLOBAL PROCEDURAL VOLUME, BASED ON REGION, (2021-2029) ($MN)
TABLE 5 NEUROVASCULAR COIL UNITS SOLD AND INTRACRANIAL ANEURYSM PROCEDURES, BASED ON COUNTRIES (2022) (NOS)
TABLE 6 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 7 TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 8 TEMPORARY AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 9 AUTOLOGOUS AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 10 RESORBABLE GELATIN SPONGE GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 11 PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
TABLE 12 PERMANENT AGENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 13 PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 14 PARTICLE AGENTS GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 15 POLYVINYL ALCOHOL (PVA) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 16 MICROSPHERES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 17 COILS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 18 COILS GLOBAL MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 19 PUSHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 20 DETACHABLE COILS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 21 LIQUID EMBOLIZATION AGENTS GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) ($MN)
TABLE 22 FLOW DIVERTERS & FLOW DISRUPTORS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 23 OTHER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 24 RADIOEMBOLIZATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 25 SUPPORTING DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 26 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
TABLE 27 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 28 NEUROLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 29 INTRACRANIAL ANEURYSM GLOBAL MARKET REVENUE,
BASED ON REGION, (2021-2029) ($MN)
TABLE 30 ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 31 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 32 ONCOLOGY GLOBAL MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 33 LIVER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 34 LUNG CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 35 OTHER CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 36 PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 37 UROLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 38 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 39 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON PROCEDURE (2021-2029) ($MN)
TABLE 40 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 41 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 42 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 43 DRUG-ELUTING BEADS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (DEB-TACE)GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 44 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (CTACE) GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 45 SELECTIVE INTERNAL RADIATION THERAPY (SIRT) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 46 TAE AND DEB-TACE PRODUCTS MATRIX
TABLE 47 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 48 HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 49 AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 50 OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
TABLE 51 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
TABLE 52 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 53 NORTH AMERICAN TEMPORARY AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 54 NORTH AMERICAN PERMANENT AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 55 NORTH AMERICAN PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 56 NORTH AMERICAN COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 57 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 58 NORTH AMERICAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 59 NORTH AMERICAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 60 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 61 NORTH AMERICAN TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 62 NORTH AMERICAN EMBOLOTHERAPY MARKET REVENUE,
BASED ON END-USER (2021-2029) ($MN)
TABLE 63 NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE,
BASED ON COUNTRY (2021-2029) ($MN)
TABLE 64 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 65 EUROPEAN TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 66 EUROPEAN PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 67 EUROPEAN PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 68 EUROPEAN COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 69 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 70 EUROPEAN NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 71 EUROPEAN ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 72 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 73 EUROPEAN TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 74 EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 75 EUROPEAN EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 76 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 77 ASIA-PACIFIC TEMPORARY AGENTS MARKET REVENUE,
BASED ON PRODUCT (2021-2029) ($MN)
TABLE 78 ASIA-PACIFIC PERMANENT AGENTS MARKET REVENUE,
BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 79 ASIA-PACIFIC PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 80 ASIA-PACIFIC COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 81 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 82 ASIA-PACIFIC NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 83 ASIA-PACIFIC ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 84 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 85 ASIA-PACIFIC TACE MARKET REVENUE, BASED ON THERAPY AGENT (2021-2029) ($MN)
TABLE 86 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 87 ASIA-PACIFIC EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 88 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 89 ROW TEMPORARY AGENTS MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
TABLE 90 ROW PERMANENT AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 91 ROW PARTICLE AGENTS MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
TABLE 92 ROW COILS MARKET REVENUE, BASED ON DEPLOYMENT (2021-2029) ($MN)
TABLE 93 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
TABLE 94 ROW NEUROLOGY MARKET REVENUE, BASED ON INDICATION (2021-2029) ($MN)
TABLE 95 ROW ONCOLOGY MARKET REVENUE, BASED ON INDICATION, (2021-2029) ($MN)
TABLE 96 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
TABLE 97 ROW TACE MARKET REVENUE, BASED ON THERAPY AGENTS (2021-2029) ($MN)
TABLE 98 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON END-USER (2021-2029) ($MN)
TABLE 99 ROW EMBOLOTHERAPY MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
TABLE 100 APPROVALS (2020-2022)
TABLE 101 ACQUISITION (2020-2022)
TABLE 102 AGREEMENTS (2020-2022)
TABLE 103 NEW PRODUCT LAUNCH (2020-2022)
TABLE 104 OTHERS (2020-2022)
TABLE 105 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
TABLE 106 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q3) ($MN)
TABLE 107 BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR SUB-SEGMENT TOTAL REVENUE, (2022)(Q3) ($MN)
TABLE 108 BOSTON SCIENTIFIC CORP.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 109 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
TABLE 110 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 111 JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 112 KANEKA CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 113 KANEKA CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 114 KANEKA CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 115 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 116 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 117 MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 118 MEDTRONIC, PLC: NEUROSCIENCES TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 119 MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
TABLE 120 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
TABLE 121 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 122 MERIT MEDICAL SYSTEMS, INC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN)
TABLE 123 MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) ($MN)
TABLE 124 PENUMBRA, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 125 PENUMBRA, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 126 PENUMBRA, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3)($MN)
TABLE 127 STRYKER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q3) ($MN)
TABLE 128 STRYKER CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q3) ($MN)
TABLE 129 STRYKER CORPORATION: TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q3) ($MN)
TABLE 130 STRYKER CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q3) ($MN)
TABLE 131 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
TABLE 132 TERUMO CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
TABLE 133 TERUMO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
LIST OF FIGURES
FIGURE 1 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: EMBOLOTHERAPY GLOBAL MARKET
FIGURE 3 EMBOLOTHERAPY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 EMBOLOTHERAPY GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 EMBOLOTHERAPY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 EMBOLOTHERAPY GLOBAL MARKET SEGMENTATION
FIGURE 7 EMBOLOTHEAPY PRODUCTS GLOBAL MARKET SEGMENTATION
FIGURE 8 EMBOLOTHEAPY APPLICATION GLOBAL MARKET SEGMENTATION
FIGURE 9 EMBOLOTHEAPY PROCEDURES GLOBAL MARKET SEGMENTATION
FIGURE 10 MARKET DYNAMICS
FIGURE 11 EMBOLOTHERAPY GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 12 CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON PHASES
FIGURE 13 CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON CONDITION
FIGURE 14 EMBOLOTHERAPY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 15 COILS GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 16 FLOW DIVERTERS & DISRUPTORS GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 17 RADIOEMBOLIZATION GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 18 NEUROVASCULAR COILS NO. OF UNITS SOLD, BASED ON REGION AND COUNTRIES, (2022) (NOS)
FIGURE 19 INTRACRANIAL ANEURYSM NO. OF PROCEDURES, BASED ON REGION AND COUNTRIES, (2022) (NOS)
FIGURE 20 EMBOLOTHEAPY GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 21 TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 22 TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 23 RESORBABLE GELATIN SPONGE GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 24 PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 25 PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 26 PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 27 PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 28 POLYVINYL ALCOHOL (PVA) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 29 COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 30 COILS GLOBAL MARKET SHARE, BASED ON DEPLOYMENT (2022 V/S 2029) (%)
FIGURE 31 PUSHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 32 DETACHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 33 LIQUID EMBOLIZATION AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 34 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON APPLICATION (2022)(%)
FIGURE 35 NEUROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 36 NEUROLOGY GLOBAL MARKET SHARE, BASED ON INDICATION (2022 V/S 2029) (%)
FIGURE 37 INTRACRANIAL ANEURYSM GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 38 ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 39 ONCOLOGY GLOBAL MARKET SHARE, BASED ON INDICATION (2022 V/S 2029) (%)
FIGURE 40 PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 41 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 42 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 43 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET SHARE, BASED ON THERAPY AGENT, (2022 V/S 2029) (%)
FIGURE 44 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (cTACE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 45 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 46 HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 47 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) CAGR (%)
FIGURE 48 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON REGIONAL MARKET REVENUE (2022) (%) ($MN)
FIGURE 49 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 50 NORTH AMERICAN TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 51 NORTH AMERICAN PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 52 NORTH AMERICAN PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 53 NORTH AMERICA COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
FIGURE 54 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
FIGURE 55 NORTH AMERICAN NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 56 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 57 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 58 NORTH AMERICAN TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 59 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 60 NORTH AMERICA EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 61 U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 62 U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 63 REST OF NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 64 REST NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 65 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 66 EUROPEAN TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 67 EUROPEAN PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 68 EUROPEAN PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 69 EUROPEAN COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
FIGURE 70 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
FIGURE 71 EUROPEAN NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 72 EUROPEAN ONCOLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 73 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 74 EUROPEAN TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 75 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 76 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 77 GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 78 GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 79 FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 80 FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 81 ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 82 ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 83 REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 84 REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 85 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 86 ASIA-PACIFIC TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 87 ASIA-PACIFIC PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 88 ASIA-PACIFIC PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 89 ASIA-PACIFIC COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
FIGURE 90 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
FIGURE 91 ASIA-PACIFIC NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 92 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 93 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 94 ASIA-PACIFIC TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 95 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 96 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 97 JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 98 JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 99 CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 100 CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 101 INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 102 INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 103 REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 104 REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 105 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCTS, (2022 V/S 2029) (%)
FIGURE 106 ROW TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 107 ROW PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 108 ROW PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 109 ROW COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029)(%)
FIGURE 110 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022)(%)
FIGURE 111 ROW NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 112 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 113 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 114 ROW TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 115 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 116 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 117 BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 118 BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 119 REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 120 REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 121 MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 122 MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 123 KEY GROWTH STRATEGIES (2020-2022)
FIGURE 124 SWOT: BALT GROUP
FIGURE 125 SWOT: BOSTON SCIENTIFIC CORPORATION
FIGURE 126 SWOT: SIRTEX MEDICAL INC.
FIGURE 127 SWOT: JOHNSON & JOHNSON
FIGURE 128 SWOT: KANEKA CORPORATION
FIGURE 129 SWOT: MEDTRONIC, PLC
FIGURE 130 SWOT: MERIT MEDICAL SYSTEMS, INC.
FIGURE 131 SWOT: PENUMBRA
FIGURE 132 SWOT: STRYKER
FIGURE 133 SWOT: TERUMO CORPORATION
FIGURE 1 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: EMBOLOTHERAPY GLOBAL MARKET
FIGURE 3 EMBOLOTHERAPY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 EMBOLOTHERAPY GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 EMBOLOTHERAPY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 EMBOLOTHERAPY GLOBAL MARKET SEGMENTATION
FIGURE 7 EMBOLOTHEAPY PRODUCTS GLOBAL MARKET SEGMENTATION
FIGURE 8 EMBOLOTHEAPY APPLICATION GLOBAL MARKET SEGMENTATION
FIGURE 9 EMBOLOTHEAPY PROCEDURES GLOBAL MARKET SEGMENTATION
FIGURE 10 MARKET DYNAMICS
FIGURE 11 EMBOLOTHERAPY GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 12 CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON PHASES
FIGURE 13 CLINICAL TRIALS OF EMBOLOTHERAPY BASED ON CONDITION
FIGURE 14 EMBOLOTHERAPY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 15 COILS GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 16 FLOW DIVERTERS & DISRUPTORS GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 17 RADIOEMBOLIZATION GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS, 2022 (%)
FIGURE 18 NEUROVASCULAR COILS NO. OF UNITS SOLD, BASED ON REGION AND COUNTRIES, (2022) (NOS)
FIGURE 19 INTRACRANIAL ANEURYSM NO. OF PROCEDURES, BASED ON REGION AND COUNTRIES, (2022) (NOS)
FIGURE 20 EMBOLOTHEAPY GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 21 TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 22 TEMPORARY AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 23 RESORBABLE GELATIN SPONGE GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 24 PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 25 PERMANENT AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 26 PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 27 PARTICLE AGENTS GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 28 POLYVINYL ALCOHOL (PVA) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 29 COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 30 COILS GLOBAL MARKET SHARE, BASED ON DEPLOYMENT (2022 V/S 2029) (%)
FIGURE 31 PUSHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 32 DETACHABLE COILS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 33 LIQUID EMBOLIZATION AGENTS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 34 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON APPLICATION (2022)(%)
FIGURE 35 NEUROLOGY GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 36 NEUROLOGY GLOBAL MARKET SHARE, BASED ON INDICATION (2022 V/S 2029) (%)
FIGURE 37 INTRACRANIAL ANEURYSM GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 38 ARTERIOVENOUS MALFORMATIONS (AVM) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 39 ONCOLOGY GLOBAL MARKET SHARE, BASED ON INDICATION (2022 V/S 2029) (%)
FIGURE 40 PERIPHERAL VASCULAR DISEASES (PVD) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 41 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 42 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 43 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) GLOBAL MARKET SHARE, BASED ON THERAPY AGENT, (2022 V/S 2029) (%)
FIGURE 44 CONVENTIONAL TRANSARTERIAL CHEMO-EMBOLIZATION (cTACE) GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 45 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 46 HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION, (2022 V/S 2029) (%)
FIGURE 47 EMBOLOTHERAPY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN) CAGR (%)
FIGURE 48 EMBOLOTHERAPY GLOBAL MARKET SHARE, BASED ON REGIONAL MARKET REVENUE (2022) (%) ($MN)
FIGURE 49 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 50 NORTH AMERICAN TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 51 NORTH AMERICAN PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 52 NORTH AMERICAN PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 53 NORTH AMERICA COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
FIGURE 54 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
FIGURE 55 NORTH AMERICAN NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 56 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 57 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 58 NORTH AMERICAN TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 59 NORTH AMERICAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 60 NORTH AMERICA EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 61 U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 62 U.S. EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 63 REST OF NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 64 REST NORTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 65 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 66 EUROPEAN TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 67 EUROPEAN PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 68 EUROPEAN PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 69 EUROPEAN COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
FIGURE 70 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
FIGURE 71 EUROPEAN NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 72 EUROPEAN ONCOLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 73 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 74 EUROPEAN TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 75 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 76 EUROPEAN EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 77 GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 78 GERMANY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 79 FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 80 FRANCE EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 81 ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 82 ITALY EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 83 REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 84 REST OF EUROPE EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 85 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCT, (2022 V/S 2029) (%)
FIGURE 86 ASIA-PACIFIC TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 87 ASIA-PACIFIC PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 88 ASIA-PACIFIC PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 89 ASIA-PACIFIC COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029) (%)
FIGURE 90 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022) (%)
FIGURE 91 ASIA-PACIFIC NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 92 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 93 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 94 ASIA-PACIFIC TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 95 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 96 ASIA-PACIFIC EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 97 JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 98 JAPAN EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 99 CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 100 CHINA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 101 INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCT AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 102 INDIA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 103 REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 104 REST OF APAC EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 105 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PRODUCTS, (2022 V/S 2029) (%)
FIGURE 106 ROW TEMPORARY AGENTS MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
FIGURE 107 ROW PERMANENT AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 108 ROW PARTICLE AGENTS MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
FIGURE 109 ROW COILS MARKET SHARE, BASED ON DEPLOYMENT, (2022 V/S 2029)(%)
FIGURE 110 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON APPLICATION, (2022)(%)
FIGURE 111 ROW NEUROLOGY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 112 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON INDICATION, (2022 V/S 2029) (%)
FIGURE 113 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON PROCEDURE, (2022 V/S 2029) (%)
FIGURE 114 ROW TACE MARKET SHARE, BASED ON THERAPY AGENTS, (2022 V/S 2029) (%)
FIGURE 115 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
FIGURE 116 ROW EMBOLOTHERAPY MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
FIGURE 117 BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 118 BRAZIL EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 119 REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 120 REST OF SOUTH AMERICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USERS (2022 V/S 2029) ($MN)
FIGURE 121 MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PRODUCTS AND APPLICATION (2022 V/S 2029) ($MN)
FIGURE 122 MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET REVENUE, BASED ON PROCEDURE AND END-USER (2022 V/S 2029) ($MN)
FIGURE 123 KEY GROWTH STRATEGIES (2020-2022)
FIGURE 124 SWOT: BALT GROUP
FIGURE 125 SWOT: BOSTON SCIENTIFIC CORPORATION
FIGURE 126 SWOT: SIRTEX MEDICAL INC.
FIGURE 127 SWOT: JOHNSON & JOHNSON
FIGURE 128 SWOT: KANEKA CORPORATION
FIGURE 129 SWOT: MEDTRONIC, PLC
FIGURE 130 SWOT: MERIT MEDICAL SYSTEMS, INC.
FIGURE 131 SWOT: PENUMBRA
FIGURE 132 SWOT: STRYKER
FIGURE 133 SWOT: TERUMO CORPORATION
